• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在进行健康检查的血糖正常人群中,瘦型非酒精性脂肪肝与新发糖尿病风险的关系:一项队列研究。

Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study.

机构信息

Dialysis Department of Nephrology Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.

Nephrology Department of Eastern Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.

出版信息

Diabetes Metab. 2021 May;47(3):101200. doi: 10.1016/j.diabet.2020.08.008. Epub 2020 Oct 16.

DOI:10.1016/j.diabet.2020.08.008
PMID:33075504
Abstract

INTRODUCTION

Convincing evidence suggests that non-alcoholic fatty liver disease (NAFLD) is associated with insulin resistance and an increased risk of diabetes; however, the association between lean NAFLD and incident diabetes, and especially differences according to gender, have not been reported thus far. This study therefore aimed to investigate whether lean NAFLD and overweight/obese NAFLD confer the same excess risk of new-onset diabetes in both genders.

METHODS

Our longitudinal study was performed in 14,482 euglycaemic adults who had participated in a health checkup programme. Fatty liver was diagnosed by abdominal ultrasonography. The outcome of interest was incident diabetes.

RESULTS

Over the median 6.0 years of follow-up, 356 cases of diabetes were diagnosed. After adjusting for sociodemographic and other potential confounders, the fully adjusted HR (95% CI) for incident diabetes in lean NAFLD vs lean without NAFLD patients was 2.58 (95% CI: 1.68-3.97) in the total cohort. Corresponding HRs were 5.53 (95% CI: 2.30-13.30) and 2.02 (95% CI: 1.24-3.31) for women and men, respectively. Post-hoc analysis revealed that the relative risk for developing diabetes was similar between lean and overweight/obese NAFLD groups whether in the entire study population or in subgroups stratified by gender (all P> 0.05).

CONCLUSION

Lean NAFLD is indeed a risk factor for incident type 2 diabetes in both genders, although the effect appeared to be more pronounced in women than in men. Further investigations are now needed to obtain a better understanding of the natural history of NAFLD in lean subjects.

摘要

简介

大量证据表明,非酒精性脂肪性肝病(NAFLD)与胰岛素抵抗和糖尿病风险增加有关;然而,瘦型 NAFLD 与新发糖尿病之间的关联,尤其是根据性别存在的差异,目前尚未有报道。因此,本研究旨在探讨瘦型 NAFLD 和超重/肥胖型 NAFLD 是否在两性中导致新发糖尿病的风险同样增加。

方法

我们的纵向研究纳入了 14482 名参加健康体检计划的血糖正常的成年人。通过腹部超声诊断脂肪肝。感兴趣的结局是新发糖尿病。

结果

在中位 6.0 年的随访期间,诊断出 356 例糖尿病。在校正了社会人口统计学和其他潜在混杂因素后,在总队列中,与非 NAFLD 的瘦型患者相比,NAFLD 的瘦型患者新发糖尿病的全调整 HR(95%CI)为 2.58(95%CI:1.68-3.97)。相应的 HR 分别为女性 5.53(95%CI:2.30-13.30)和男性 2.02(95%CI:1.24-3.31)。事后分析显示,无论在整个研究人群中还是在按性别分层的亚组中,发生糖尿病的相对风险在瘦型和超重/肥胖型 NAFLD 组之间相似(所有 P>0.05)。

结论

瘦型 NAFLD 确实是两性中发生 2 型糖尿病的一个危险因素,尽管这种效应在女性中似乎比男性更明显。现在需要进一步的研究来更好地了解瘦型人群中 NAFLD 的自然史。

相似文献

1
Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study.在进行健康检查的血糖正常人群中,瘦型非酒精性脂肪肝与新发糖尿病风险的关系:一项队列研究。
Diabetes Metab. 2021 May;47(3):101200. doi: 10.1016/j.diabet.2020.08.008. Epub 2020 Oct 16.
2
Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study.瘦型非酒精性脂肪性肝病与糖尿病的发生:队列研究。
Eur J Endocrinol. 2019 Aug;181(2):185-192. doi: 10.1530/EJE-19-0143.
3
Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.瘦型非酒精性脂肪性肝病与中国西北地区健康人群 2 型糖尿病发病风险的关联:一项 2 年随访期的回顾性队列研究。
Front Endocrinol (Lausanne). 2023 Jun 26;14:1173757. doi: 10.3389/fendo.2023.1173757. eCollection 2023.
4
Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis.非酒精性脂肪肝与 2 型糖尿病发病风险的关系:文献综述和荟萃分析。
Diabetes Res Clin Pract. 2023 Jun;200:110699. doi: 10.1016/j.diabres.2023.110699. Epub 2023 May 9.
5
Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.非肥胖或非消瘦的非酒精性脂肪性肝病与 2 型糖尿病患者的癌症风险增加相关。
BMJ Open Diabetes Res Care. 2023 Feb;11(1). doi: 10.1136/bmjdrc-2022-003066.
6
Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).脂肪肝指数可预测前驱糖尿病、2型糖尿病和非酒精性脂肪性肝病(NAFLD)的发病风险。
Ann Med. 2021 Dec;53(1):1256-1264. doi: 10.1080/07853890.2021.1956685.
7
Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.瘦型非酒精性脂肪性肝病(NAFLD)患者的临床特征和代谢特征及其与肥胖和超重 NAFLD 的比较。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
8
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.全球非肥胖或消瘦非酒精性脂肪性肝病的患病率、发病率和结局:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.
9
Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese.非酒精性脂肪性肝病与非肥胖人群中糖尿病发病风险的关系。
Nutr Metab Cardiovasc Dis. 2019 May;29(5):489-495. doi: 10.1016/j.numecd.2019.01.016. Epub 2019 Feb 7.
10
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.瘦型非酒精性脂肪性肝病患者的肝脏和心血管损伤,及其与内脏肥胖的关系。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

引用本文的文献

1
Prevalence of MAFLD in the U.S. based on NHANES 2009-2018: differences in demographic characteristics, physical indices and lifestyle conditions.基于2009 - 2018年美国国家健康与营养检查调查(NHANES)的美国代谢功能障碍相关脂肪性肝病(MAFLD)患病率:人口统计学特征、身体指标和生活方式状况的差异
BMC Gastroenterol. 2025 May 2;25(1):329. doi: 10.1186/s12876-025-03956-2.
2
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women.绝经后女性的代谢功能障碍相关脂肪性肝病:患病率、发病机制及基于性别的治疗方法
Biomedicines. 2025 Apr 2;13(4):855. doi: 10.3390/biomedicines13040855.
3
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.
瘦人群与非瘦人群中代谢功能障碍相关脂肪性肝病的长期结局及风险修饰因素
Clin Mol Hepatol. 2025 Jan;31(1):74-89. doi: 10.3350/cmh.2024.0631. Epub 2024 Oct 23.
4
Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.糖尿病代谢相关脂肪性肝病患者的死亡率结局:非肥胖与肥胖个体。
Sci Rep. 2024 May 17;14(1):11320. doi: 10.1038/s41598-024-61896-5.
5
Update in lean metabolic dysfunction-associated steatotic liver disease.瘦素代谢功能障碍相关脂肪性肝病的最新进展。
World J Hepatol. 2024 Mar 27;16(3):452-464. doi: 10.4254/wjh.v16.i3.452.
6
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.肥胖的临床分类及其对代谢功能障碍相关脂肪性肝病和治疗的影响
Diabetes Metab Syndr Obes. 2023 Oct 25;16:3303-3329. doi: 10.2147/DMSO.S431251. eCollection 2023.
7
Global burden of type 2 diabetes attributable to non-high body mass index from 1990 to 2019.2019 年归因于非高身体质量指数的 2 型糖尿病全球负担。
BMC Public Health. 2023 Jul 12;23(1):1338. doi: 10.1186/s12889-023-15585-z.
8
Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.瘦型非酒精性脂肪性肝病与中国西北地区健康人群 2 型糖尿病发病风险的关联:一项 2 年随访期的回顾性队列研究。
Front Endocrinol (Lausanne). 2023 Jun 26;14:1173757. doi: 10.3389/fendo.2023.1173757. eCollection 2023.
9
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes.瘦型/正常体重 2 型糖尿病的病理生理学的现有知识。
Int J Mol Sci. 2022 Dec 30;24(1):658. doi: 10.3390/ijms24010658.
10
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.代谢(功能)相关正常体重型脂肪性肝病。
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):638-651. doi: 10.1038/s41575-022-00635-5. Epub 2022 Jun 16.